GIGANUCLEASE Trademark

Trademark Overview


On Wednesday, January 16, 2002, a trademark application was filed for GIGANUCLEASE with the United States Patent and Trademark Office. The USPTO has given the GIGANUCLEASE trademark a serial number of 76359549. The federal status of this trademark filing is CANCELLED - SECTION 8 as of Friday, September 21, 2012. This trademark is owned by CELLECTIS S.A.. The GIGANUCLEASE trademark is filed in the Chemical Products, Pharmaceutical Products, and Computer & Software Services & Scientific Services categories with the following description:

Chemicals, biochemical, biotechnological and bacteriological products namely, polypeptides for in vivo and invitro genetic engineering, natural and engineered meganuclease and endonuclease, nucleic acid vectors encoding the natural or engineered meganuclease or endonuclease or nucleic acid vectors comprising their recognition and cleavage site; ready to use genomic recombination system comprised primarily of reagents for scientific use; cells engineered by meganuclease recombination systems for scientific research use and therapeutic use, chemical agents, biochemical, biotechnologic and bacteriological products for use in scientific research laboratories and control laboratories namely cells, reagents, and culture media; diagnostic reagents for scientific use; proteins for use in scientific research; biotechnological preparations used as molecular scissors in scientific research

Pharmaceutical, veterinary, and health care products, namely polypeptides for in vivo and in vitro genetic engineering for use in the treatment of cystic fibrosis, Duchesne muscular dystrophy, and Alpha 1 antitrypsin disease; natural and engineered meganucleases and endonucleases, nucleic acid vectors encoding the natural or engineered meganuclease or endonuclease or nucleic acid vectors comprising their recognition and cleavage site, all for use in the treatment of sickle cell anemia, X-SciD, and Rs-SciD; ready to use genomic recombination system comprised primarily of meganuclease recombination system for use in the treatment of muscular dystrophy; cells engineered by meganuclease recombination system for use in the treatment of genetic and viral disease, microorganism cultures and bacteriological preparations for use in the treatment of genetic and viral disease; chemotherapeutic preparations for use in the treatment of cancer; diagnostic preparations for clinical medical use

Scientific and industrial research; research for others in genetic, medical, pharmaceutical, and veterinary fields; research for others in chemistry, biology, biochemistry, molecular biology, bacteriology; scientific analysis services, research and development for others of techniques of biochemical analysis, biological analysis, molecular biology techniques, research and development of new molecules intended for industry, scientific laboratory services; conducting scientific research studies relating to engineering, natural, and engineered meganuclease and endonuclease, and meganuclease recombination systems; licensing of patents and of intellectual property; computer programming for others; and development for others of software programs and multimedia products
giganuclease

General Information


Serial Number76359549
Word MarkGIGANUCLEASE
Filing DateWednesday, January 16, 2002
Status710 - CANCELLED - SECTION 8
Status DateFriday, September 21, 2012
Registration Number2988451
Registration DateTuesday, August 30, 2005
Mark Drawing1000 - Typeset: Word(s) / letter(s) / number(s)
Published for Opposition DateTuesday, June 7, 2005

Trademark Statements


Goods and ServicesChemicals, biochemical, biotechnological and bacteriological products namely, polypeptides for in vivo and invitro genetic engineering, natural and engineered meganuclease and endonuclease, nucleic acid vectors encoding the natural or engineered meganuclease or endonuclease or nucleic acid vectors comprising their recognition and cleavage site; ready to use genomic recombination system comprised primarily of reagents for scientific use; cells engineered by meganuclease recombination systems for scientific research use and therapeutic use, chemical agents, biochemical, biotechnologic and bacteriological products for use in scientific research laboratories and control laboratories namely cells, reagents, and culture media; diagnostic reagents for scientific use; proteins for use in scientific research; biotechnological preparations used as molecular scissors in scientific research
Goods and ServicesPharmaceutical, veterinary, and health care products, namely polypeptides for in vivo and in vitro genetic engineering for use in the treatment of cystic fibrosis, Duchesne muscular dystrophy, and Alpha 1 antitrypsin disease; natural and engineered meganucleases and endonucleases, nucleic acid vectors encoding the natural or engineered meganuclease or endonuclease or nucleic acid vectors comprising their recognition and cleavage site, all for use in the treatment of sickle cell anemia, X-SciD, and Rs-SciD; ready to use genomic recombination system comprised primarily of meganuclease recombination system for use in the treatment of muscular dystrophy; cells engineered by meganuclease recombination system for use in the treatment of genetic and viral disease, microorganism cultures and bacteriological preparations for use in the treatment of genetic and viral disease; chemotherapeutic preparations for use in the treatment of cancer; diagnostic preparations for clinical medical use
Goods and ServicesScientific and industrial research; research for others in genetic, medical, pharmaceutical, and veterinary fields; research for others in chemistry, biology, biochemistry, molecular biology, bacteriology; scientific analysis services, research and development for others of techniques of biochemical analysis, biological analysis, molecular biology techniques, research and development of new molecules intended for industry, scientific laboratory services; conducting scientific research studies relating to engineering, natural, and engineered meganuclease and endonuclease, and meganuclease recombination systems; licensing of patents and of intellectual property; computer programming for others; and development for others of software programs and multimedia products

Classification Information


International Class001 - Chemicals used in industry, science and photography, as well as in agriculture, horticulture and forestry; unprocessed artificial resins; unprocessed plastics; manures; fire extinguishing compositions; tempering and soldering preparations; chemical substances for preserving foodstuffs; tanning substances; adhesives used in industry.
US Class Codes001, 005, 006, 010, 026, 046
Class Status Code2 - Sec. 8 - Entire Registration
Class Status DateFriday, September 21, 2012
Primary Code001
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes006, 018, 044, 046, 051, 052
Class Status Code2 - Sec. 8 - Entire Registration
Class Status DateFriday, September 21, 2012
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

International Class042 - Scientific and technological services and research and design relating thereto; industrial analysis and research services; design and development of computer hardware and software.
US Class Codes100, 101
Class Status Code2 - Sec. 8 - Entire Registration
Class Status DateFriday, September 21, 2012
Primary Code042
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History


Party NameCELLECTIS S.A.
Party Type30 - Original Registrant
Legal Entity Type03 - Corporation
Address75724 Paris Cedex 15
FR

Party NameCELLECTIS S.A.
Party Type20 - Owner at Publication
Legal Entity Type03 - Corporation
Address75724 Paris Cedex 15
FR

Party NameCELLECTIS S.A.
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
Address75724 Paris Cedex 15
FR

Trademark Events


Event DateEvent Description
Friday, September 21, 2012CANCELLED SEC. 8 (6-YR)
Tuesday, August 30, 2005EXPARTE APPEAL TERMINATED
Tuesday, August 30, 2005REGISTERED-PRINCIPAL REGISTER
Tuesday, June 7, 2005PUBLISHED FOR OPPOSITION
Wednesday, May 18, 2005NOTICE OF PUBLICATION
Friday, February 18, 2005LAW OFFICE PUBLICATION REVIEW COMPLETED
Tuesday, February 15, 2005ASSIGNED TO LIE
Monday, January 31, 2005ASSIGNED TO LIE
Wednesday, January 26, 2005APPROVED FOR PUB - PRINCIPAL REGISTER
Friday, August 13, 2004JURISDICTION RESTORED TO EXAMINING ATTORNEY
Wednesday, July 28, 2004PAPER RECEIVED
Tuesday, August 10, 2004PAPER RECEIVED
Tuesday, August 10, 2004EX PARTE APPEAL-INSTITUTED
Wednesday, August 4, 2004EXPARTE APPEAL RECEIVED AT TTAB
Monday, January 26, 2004FINAL REFUSAL MAILED
Friday, October 24, 2003CORRESPONDENCE RECEIVED IN LAW OFFICE
Thursday, November 20, 2003CASE FILE IN TICRS
Friday, October 24, 2003PAPER RECEIVED
Wednesday, July 23, 2003LETTER OF SUSPENSION MAILED
Monday, April 7, 2003CORRESPONDENCE RECEIVED IN LAW OFFICE
Monday, April 7, 2003PAPER RECEIVED
Friday, March 14, 2003CORRESPONDENCE RECEIVED IN LAW OFFICE
Friday, March 14, 2003PAPER RECEIVED
Friday, March 7, 2003LETTER OF SUSPENSION MAILED
Wednesday, December 11, 2002CORRESPONDENCE RECEIVED IN LAW OFFICE
Wednesday, December 11, 2002PAPER RECEIVED
Tuesday, March 26, 2002CORRESPONDENCE RECEIVED IN LAW OFFICE
Wednesday, June 19, 2002NON-FINAL ACTION MAILED
Tuesday, March 26, 2002PAPER RECEIVED
Wednesday, April 3, 2002ASSIGNED TO EXAMINER